Market Place
Sourcing Support
CARB-X Funds Debiopharm’s Antibiotic for Drug-Resistant Gonorrhea
21 Nov 2024 //
BUSINESSWIRE
Debiopharm Showcases Anti-Staphylococcal Program At IDWeek 2024
15 Oct 2024 //
BUSINESSWIRE
Debiopharm Recognizes Japanese Cancer Research At JCA Meeting
23 Sep 2024 //
BUSINESSWIRE
Debiopharm & WhiteLab Partner For Oncology Drug Design
16 Sep 2024 //
BUSINESSWIRE
ITM Licenses CA IX-Targeted Radiopharmaceuticals From Debiopharm
12 Sep 2024 //
GLOBENEWSWIRE
Debiopharm Doses First Patients In Debio 4326 Phase 3 Trial
09 Sep 2024 //
BUSINESSWIRE
Debiopharm Sponsors 8th Annual World AMR Conference
27 Aug 2024 //
BUSINESSWIRE
Debiopharm, Genome Agree On First-In-Class Oncology ADC Family
03 Jun 2024 //
BUSINESSWIRE
MEDSIR, Debiopharm: Breast Cancer Combination Therapy Exploration
28 May 2024 //
BUSINESSWIRE
Debiopharm to Showcase Results of DDR Inhibitors at the 2024 AACR Conference
04 Apr 2024 //
BUSINESSWIRE
Ubiquigent and Debiopharm team up to advance USP1 inhibitor
27 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Ubiquigent and Debiopharm Enter Agreement to Support for Debio 0432
26 Mar 2024 //
BUSINESSWIRE
Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research
07 Mar 2024 //
BUSINESSWIRE
TransCode Therapeutics and Debiopharm Announce Collaboration
29 Jan 2024 //
GLOBENEWSWIRE
Genialis and Debiopharm Set Up Biomarker Discovery Collaboration
25 Jan 2024 //
BUSINESSWIRE
Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership
10 Jan 2024 //
BUSINESSWIRE
Debiopharm Extends SunRock Biopharma Partnership for ADC
08 Jan 2024 //
BUSINESSWIRE
Debiopharm and Repare Therapeutics Partner to Explore PKMYT1 and WEE1
04 Jan 2024 //
BUSINESSWIRE
Debiopharm Innovation Fund Launches New Seed Funding Activity
28 Sep 2023 //
BUSINESSWIRE
Debiopharm Recognizes Pioneering Japanese Cancer Research During Award Ceremony
25 Sep 2023 //
BUSINESSWIRE
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates
21 Sep 2023 //
BUSINESSWIRE
Debiopharm Joins Discussions With IHO to Fight Anti-Microbial Resistance
06 Sep 2023 //
BUSINESSWIRE
Altis Labs Raises US $6 Million in Seed Funding Co-Led by Debiopharm
21 Jun 2023 //
BUSINESSWIRE
Debiopharm Shares Oncology Program Updates At Asco 2023 For Novel Wee1 Inhibitor
01 Jun 2023 //
PR NEWSWIRE
DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER
30 May 2023 //
PR NEWSWIRE
Debiopharm doses first patient in Phase I trial of cancer combo therapy
30 May 2023 //
CLINICAL TRIALS ARENA
Debiopharm Partners with Genedata to Digitalize Translational Research
25 May 2023 //
PR NEWSWIRE
Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective Wee1 Inhibitor
17 May 2023 //
PR NEWSWIRE
Debiopharm Announces Launch Of The Phase 1/2 Galuci Study
22 Mar 2023 //
PR NEWSWIRE
Debiopharm Extends Dna Damage Repair Footprint With Oncology Pipeline Entry
02 Mar 2023 //
PR NEWSWIRE
Debiopharm Applies Extended-Release Formulation Expertise
12 Jan 2023 //
PR NEWSWIRE
Debiopharm leads $6M round for YonaLink to Scale Global Growth
09 Nov 2022 //
PRNEWSWIRE
Debiopharm Launches A Wazoku Innovation Challenge For Drug Conjugate Technology
22 Sep 2022 //
PRNEWSWIRE
Debiopharm Announces Oncology Research Advancements At AACR 2022
11 Apr 2022 //
PRNEWSWIRE
Debiopharm, Aspen Partner To Launch Prostate Cancer Drug Trelstar In S. Africa
01 Feb 2022 //
PRNEWSWIRE
Debiopharm Further Explores the Potential of Debio 0123 In Phase 1 Cancer Study
15 Dec 2021 //
PRNEWSWIRE
CARB-X Funds the 3rd Round of Debiopharm`s Targeted Antibiotic Program
19 Oct 2021 //
BIOSPACE
Debiopharm and Dexa Medica Launch Triptorelin Collaboration
07 Oct 2021 //
PRNEWSWIRE
Debiopharm encourages breakthough cancer research in Japan
05 Oct 2021 //
PHARMABIZ
Debiopharm encourages breakthough cancer research in Japan
05 Oct 2021 //
PHARMABIZ
Debiopharm Encourages Breakthrough Cancer Research inJapan JCA Mauvernay Award
03 Oct 2021 //
PRNEWSWIRE
Debiopharm, Ubix Therapeutics ink research pact
16 Jun 2021 //
PHARMABIZ
Debiopharm`s CD37 ADC Shows Promising Ph II Results
14 Jun 2021 //
BIOSPACE
Merck KGaA earmarks $855M for Debiopharm`s programmed cell death promoting drug
02 Mar 2021 //
ENDPTS
Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt
01 Mar 2021 //
PRNEWSWIRE
Genome & Company and Debiopharm Join Forces To Create New Highly Specific
25 Feb 2021 //
PRNASIA
Genome & Company and Debiopharm to create precise Cancer therapies
24 Feb 2021 //
BIOSPECTRUMASIA
Debiopharm begins Phase II trial of alisporivir against Covid-19 in France
20 Jan 2021 //
CLINICALTRIALSARENA
Phase II Research Against Covid-19 Launched in France Debiopharm`s Alisporivir
19 Jan 2021 //
PRNEWSWIRE
Phase II Research Against Covid-19 Launched in France Debiopharm`s Alisporivir
18 Jan 2021 //
PRNEWSWIRE
Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai`s
14 Jan 2021 //
PRNEWSWIRE
Debiopharm Launches TrilynX - A Large-Scale Phase III Clinical Trial
01 Oct 2020 //
PRNEWSWIRE
Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant
01 Oct 2020 //
PRNEWSWIRE
Debiopharm to Present Late Breaking Head &
17 Sep 2020 //
BIOSPACE
Debiopharm`s New Generation Radionuclide Therapy Advances Into Clinical Research
26 Aug 2020 //
PRNEWSWIRE
Debiopharm`s New Generation Radionuclide Therapy Advances Into Clinical Research
26 Aug 2020 //
PRNEWSWIRE
DEBIOPHARM’S IAP ANTAGONIST SIGNIFICANTLY IMPROVES OVERALL SURVIVAL
13 Aug 2020 //
DEBIOPHARM
Verity Pharma to commercialise Debiopharm’s hormone therapy, Trelstar in US
10 Jun 2020 //
PHARMABIZ
Debiopharm partners with Verity for the exclusive US of Trelstar®
09 Jun 2020 //
PRNEWSWIRE
Acquisition of Debiopharm`s Investment Portfolio Company Kaiku Health
26 May 2020 //
PR NEWSWIRE
